bz-423 has been researched along with Severe Combined Immunodeficiency in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aslam, MN; Bhagavathula, N; Glick, GD; Hanosh, A; Johnson, K; Kang, S; Nerusu, KC; Opipari, AW; Sundberg, TB; Varani, J | 1 |
1 other study(ies) available for bz-423 and Severe Combined Immunodeficiency
Article | Year |
---|---|
7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423), a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined immunodefici
Topics: Animals; Benzodiazepines; Cell Proliferation; Disease Models, Animal; Humans; Keratinocytes; Mice; Mice, SCID; Psoriasis; Severe Combined Immunodeficiency; Skin Transplantation | 2008 |